Literature DB >> 23634384

Formularies, costs, and quality of care: Formulary restrictions are not the answer, especially for epilepsy.

David M Labiner1, Kendra W Drake.   

Abstract

The goal of treating an individual with epilepsy is to have no seizures and no side effects. Limiting availability of medications appears to be a simple way of controlling costs of patient care. This approach potentially jeopardizes both efficacy and safety. We argue, in this edition of Current Controversies, that limiting costs by restricting formularies is detrimental to the patients from an efficacy, safety, and cost perspective.

Entities:  

Year:  2013        PMID: 23634384      PMCID: PMC3613218          DOI: 10.1212/CPJ.0b013e318283ff65

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN: 2163-0402


  4 in total

Review 1.  ILAE treatment guidelines: evidence-based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes.

Authors:  Tracy Glauser; Elinor Ben-Menachem; Blaise Bourgeois; Avital Cnaan; David Chadwick; Carlos Guerreiro; Reetta Kalviainen; Richard Mattson; Emilio Perucca; Torbjorn Tomson
Journal:  Epilepsia       Date:  2006-07       Impact factor: 5.864

2.  Generic antiepileptic drugs and associated medical resource utilization in the United States.

Authors:  D M Labiner; P E Paradis; R Manjunath; M S Duh; M-H Lafeuille; D Latrémouille-Viau; P Lefebvre; S L Helmers
Journal:  Neurology       Date:  2010-04-14       Impact factor: 9.910

3.  Early identification of refractory epilepsy.

Authors:  P Kwan; M J Brodie
Journal:  N Engl J Med       Date:  2000-02-03       Impact factor: 91.245

Review 4.  Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society.

Authors:  J A French; A M Kanner; J Bautista; B Abou-Khalil; T Browne; C L Harden; W H Theodore; C Bazil; J Stern; S C Schachter; D Bergen; D Hirtz; G D Montouris; M Nespeca; B Gidal; W J Marks; W R Turk; J H Fischer; B Bourgeois; A Wilner; R E Faught; R C Sachdeo; A Beydoun; T A Glauser
Journal:  Neurology       Date:  2004-04-27       Impact factor: 9.910

  4 in total
  2 in total

1.  Formularies, costs, and quality of care.

Authors:  Nitin K Sethi
Journal:  Neurol Clin Pract       Date:  2013-06

2.  Impact of Formulary Restrictions on Antiepileptic Drug Dispensation Outcomes.

Authors:  Darshan Mehta; Matthew Davis; Andrew J Epstein; Andrew Lee
Journal:  Neurol Ther       Date:  2020-05-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.